Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Federico Villa
Observed names:
F Villa,
Villa, Federico
Institutions:
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”,
Italian Medicines Agency,
AstraZeneca (Italy)
Observed institutions:
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”,
Italian Medicines Agency,
AstraZeneca (Italy)
ORCID:
0000-0001-9772-5734
Observed ORCID:
0000-0001-9772-5734
OpenAlex ID:
A5074689088
Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency
2019
·
Federico Villa
, Michaela Tutone
, et al.
·
Health Policy
·
57
Monitoring the community use of antibiotics in Italy within the National Action Plan on antimicrobial resistance
2020
·
Agnese Cangini
, Filomena Fortinguerra
, et al.
·
British Journal of Clinical Pharmacology
·
43
PDF
Orphan Drug Prices and Epidemiology of Rare Diseases: A Cross-Sectional Study in Italy in the Years 2014–2019
2022
·
Federico Villa
, Aurora Di Filippo
, et al.
·
Frontiers in Medicine
·
19
PDF
Variables affecting pricing of orphan drugs: the Italian case
2021
·
Claudio Jommi
, Elisabetta Listorti
, et al.
·
Orphanet Journal of Rare Diseases
·
18
PDF
How Do Drug Regulatory Bodies Deal With Potential Innovative Therapies?
2020
·
Michaela Tutone
, Federico Villa
, et al.
·
Therapeutic Innovation & Regulatory Science
·
10
Accesso precoce al mercato: dalle approvazioni condizionate di EMA agli accordi negoziali particolari di AIFA
2018
·
Federico Villa
, Claudio Jommi
, et al.
·
Global & Regional Health Technology Assessment
·
8
PDF
Programmi di early access dei farmaci e managed entry agreement in Italia: i risultati di un Focus Group (programmi di early access e managed entry agreement)
2021
·
Claudio Jommi
, Patrizio Armeni
, et al.
·
Recenti Progressi in Medicina
·
7
How medicines are used in Italy: Data from the National Report 2018
2019
·
Agnese Cangini
, Federico Villa
, et al.
·
Health Policy and Technology
·
6
Quanto vale la negoziazione del prezzo di un nuovo farmaco in Italia?
2020
·
Federico Villa
, Claudio Jommi
, et al.
·
Recenti Progressi in Medicina
·
3
New drug pricing criteria in Italy: considerations and proposals to support value and innovation
2021
·
Francesca Patarnello
, Federico Villa
·
Global & Regional Health Technology Assessment
·
2
PDF
Appropriatezza prescrittiva, uso e consumo degli antibiotici in Italia. Un estratto del Rapporto Nazionale 2018 sull’uso degli antibiotici in Italia
2020
·
Agnese Cangini
, Carlo Gagliotti
, et al.
·
Recenti Progressi in Medicina
·
2
How Do Drug Regulatory Bodies Deal With Potential Innovative Therapies?
2019
·
Michaela Tutone
, Federico Villa
, et al.
·
Therapeutic Innovation & Regulatory Science
·
1
Value generated by the multiplier effect of investments by the pharmaceutical industry in Italy: proposals to promote competitiveness and attractiveness
2022
·
Francesca Patarnello
, Emiliano Briante
, et al.
·
Global & Regional Health Technology Assessment
PDF
POSC207 Variables Affecting Pricing of Orphan Drugs: The Italian Case
2022
·
C Jommi
, E Listorti
, et al.
·
Value in Health
Show more works
View as search
Works count:
15
Citation count:
176
H-index:
7
I10-index:
5
Year
Topic
Type